Trial Profile
A Randomized, Double Blind, Single Dose, Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805 in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Oct 2023
Price :
$35
*
At a glance
- Drugs JNJ 56914845 (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 15 Jul 2013 Primary endpoint 'Left-ventricular-ejection-fraction' has been met, according to results published in Antimicrobial Agents and Chemotherapy.
- 15 Jul 2013 Results published in Antimicrobial Agents and Chemotherapy.
- 13 Jul 2012 Actual initiation date changed from Aug 2011 to Sept 2011 as reported by ClinicalTrials.gov record.